Integra Lifesciences recently received an FDA warning letter pertaining to quality systems issues at several facilities.

In a regulatory filing on Monday, Integra LifeSciences (IART) said that on December 19, 2024, a subsidiary received a warning letter from the ...

Investors in Integra LifeSciences Holdings Corporation IART need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $5 Callhad some of ...

06:46 EST Integra LifeSciences (IART) reaffirms Q4 revenue view $441M-$451M, consensus $445.15M Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and ...

Integra LifeSciences Holdings Corporation IART is well-poised to grow in the coming quarter, driven by healthy sales growth ...

Try Integra LifeSciences Holdings ( NASDAQ:IART ) Third Quarter 2024 Results Key Financial Results Revenue: US$380.8m (flat... On Monday, Integra LifeSciences Holdings Corporation (NASDAQ ...

Integra LifeSciences' Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline. Vandana Singh Integra LifeSciences Posts ...

Invesco Small Cap Value Fund highlighted stocks like Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the third quarter 2024 investor letter. Integra LifeSciences Holdings Corporation ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the ...